AML

Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform

Retrieved on: 
Monday, April 8, 2024
Find, White blood cell, AML, Patient, Acute myeloid leukemia, Cancer, AACR, Cryopreservation, Therapy, Pharmaceutical industry

“We are very pleased to share the result of our innovative sample handling study with the cancer community at AACR 2024.

Key Points: 
  • “We are very pleased to share the result of our innovative sample handling study with the cancer community at AACR 2024.
  • The ability to derive a high-quality assessment of the response to treatment based on the results of cryopreserved samples is an important innovation.
  • It has been previously thought that frozen samples could not be effectively thawed and used for cell viability assays.
  • While Notable will continue to evaluate and validate these sample handling methodologies, these data open the door to the use of cryopreserved samples from retrospective cohorts.

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

Retrieved on: 
Monday, April 8, 2024
Sarah Cannon Research Institute, B-cell leukemia, AML, B-ALL, Patient, Webcast, Neoplasm, Acute myeloid leukemia, Cancer, Syndrome, Spacecraft, Camptothecin, AACR, DLT, PALO, Antibody, Drug development, Safety, Infrared spectroscopy correlation table, MDS, Therapy, ADC, Drug resistance, Pharmaceutical industry

PALO ALTO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • We are still in dose escalation and are starting to see tumor reduction after only two doses.
  • The study's main objective is to determine a safe dose and schedule for VIP236 for further clinical development.
  • As the study progresses through the dose escalation, Vincerx will present additional Phase 1 data for VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.
  • An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.

Quantexa Recognized in Chartis’s Inaugural Financial Crime and Compliance 50 Rankings as Top Ranked Solution Provider

Retrieved on: 
Monday, April 8, 2024
Research, Danske Bank, AML, Augmented Analytics, KYC, AI, Standard Chartered, ING, BNY Mellon, HSBC, Cryptocurrency

This report marks the first time Chartis Research has ranked vendors in the FinCrime and compliance space.

Key Points: 
  • This report marks the first time Chartis Research has ranked vendors in the FinCrime and compliance space.
  • Quantexa’s AI-enabled financial crime and compliance solutions landed category leader positions in Entity Management, Data Enrichment, and Augmented Analytics, ranking sixth overall out of an initial set of almost 300 vendors considered for the report.
  • Quantexa’s solutions were recognized for helping banks detect real risk with proactive alert management and streamlining the process of end-to-end monitoring to effectively identify and mitigate financial crime.
  • Alexon Bell, Chief Product Officer, Financial Crime, at Quantexa, said: “It’s gratifying to receive recognition as a leading vendor in the global FinCrime and Compliance market.

Prem Labs Receives $14M Seed Funding to Revolutionize Proprietary AI Model Generation, Backed by Major Film Producer

Retrieved on: 
Friday, April 5, 2024
SingularityNET, Marvel Studios, OpenAI, University, Labs, AML, Risk, Intelligence, KYC, Research, AI, SUPSI, Doctor of Philosophy, Prem, USI, Commerce, GRC, Applied science, Privacy, Medical device

David Maisel has come aboard not only as an investor, but as part of Prem Labs’ Advisory Board.

Key Points: 
  • David Maisel has come aboard not only as an investor, but as part of Prem Labs’ Advisory Board.
  • According to Prem Labs, Maisel’s involvement demonstrates the company’s commitment to leveraging generative AI for enhancing intellectual properties, backed by a strong network of entrepreneurs and global investors.
  • Prem Labs developed Prem 1B Small Language Models (SLMs), a model trained from scratch for efficiency and fine-tuning.
  • “Prem Labs envisions a future where every individual, company, and country has access to powerful, private, and personalized AI models,” says Simone Giacomelli, CEO of Prem Labs.

Toobit Integrates with CODE Travel Rule Solution, Strengthening Compliance and Security

Retrieved on: 
Friday, April 5, 2024
Partnership, Financial Action Task Force, FATF, CODE, Environment, AML, Safety, Cryptocurrency

The integration with the CODE Travel Rule solution is a testament to Toobit's dedication to compliance, safety, and the provision of technology-based solutions that not only meet but exceed the international standards for anti-money laundering (AML) compliance.

Key Points: 
  • The integration with the CODE Travel Rule solution is a testament to Toobit's dedication to compliance, safety, and the provision of technology-based solutions that not only meet but exceed the international standards for anti-money laundering (AML) compliance.
  • The Financial Action Task Force's Travel Rule is a critical regulatory standard aimed at curbing money laundering and terrorist financing.
  • By partnering with CODE, a Travel Rule solution embraced by major exchanges, Toobit demonstrates its commitment to the highest levels of compliance and security.
  • The cryptocurrency community warmly welcomes Toobit's integration into the CODE alliance, a testament to its dedication to enhancing the trading environment through compliance with global standards.

PaySaxas Launching, Offers Global Payments, Provides Unique Solutions to Import Export Market

Retrieved on: 
Friday, April 5, 2024
JPY, Chemical oxygen demand, AML, KYC, GBP, MSB, OTC, Safety, USDT, Cryptocurrency

VANCOUVER, CANADA, April 05, 2024 (GLOBE NEWSWIRE) -- PaySaxas, the newest entrant of the cross border transaction industry, has announced it has launched global payments, providing exclusive and unique solutions for international trade, including in-house crypto OTC.

Key Points: 
  • VANCOUVER, CANADA, April 05, 2024 (GLOBE NEWSWIRE) -- PaySaxas, the newest entrant of the cross border transaction industry, has announced it has launched global payments, providing exclusive and unique solutions for international trade, including in-house crypto OTC.
  • The PaySaxas Smart Payments Platform focuses on specific features, that have long been in demand by the global trade industry.
  • The emerging trend provides customers immediate and direct access to the decision makers rather than lengthy delays.
  • With multilingual support and a team that understands the pains of global trade, the PaySaxas solution offers customers more payment solutions, and less hassle with daily transactions, leaving them to focus on their revenue and business growth.

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, April 4, 2024
Fulvestrant, KICKSTART, Survival, NSCLC, AML, Patient, Acute myeloid leukemia, Cancer, Hope, Pembrolizumab, Lung cancer, Therapy, Breast cancer, Safety, Cox, PFS, Interval (mathematics), Effector, Pharmaceutical industry

The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p≤0.2.

Key Points: 
  • The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p≤0.2.
  • The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respectively.
  • There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm.
  • “We sincerely appreciate the contributions of all the patients, their families, and trial site professionals who contributed to the execution of the trial.

BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Thursday, April 4, 2024
Sickle cell disease, Bluebird bio, AML, Telephone, Blue, Patient, History, News, LLP, CLASS, Complaint, NEXT, COST, FDA, Court, Food, Cryptocurrency

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of bluebird bio investors who were adversely affected by alleged securities fraud between April 24, 2023 and December 8, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BLUE investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

bluebird bio, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – BLUE

Retrieved on: 
Wednesday, April 3, 2024
Sickle cell disease, AML, Blue, Patient, History, News, Complaint, BLUE, Fraud, NEXT, FDA, Bluebird bio, Food, Security (finance)

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).
  • Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors

Retrieved on: 
Tuesday, April 2, 2024
Sickle cell disease, AML, District court, Patient, History, News, FDA, Court, Pharmaceutical industry

Investors have until May 28, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 28, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The lawsuit alleges that Blue provided investors with false and misleading information in order to bolster investor expectations and share prices.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.